中国式MNC,迎来关键一年

药渡
Jun 07

近日,远大医药创新药STC3141在脓毒症II期临床研究中成功达到终点的消息,刷屏医药圈。消息火爆背后,一向低调的远大医药来到聚光灯下。这家药企在仿制药集采压力下,已经收到创新转型的回报。那么,这家其实有着中国式MNC之称的药企,有着怎样的战略布局?1刷屏的STC3141市场有多大STC3141是远大医药自主开发的一款全球创新性小分子化合物。其不仅可以直接中和胞外组蛋白的毒性,而且可阻断组蛋白诱发...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10